title: Prescription opioid abuse: challenges and opportunities for payers.
abstract: OBJECTIVE
  Prescription opioid abuse and addiction are serious problems with growing societal and medical costs, resulting in billions of dollars of excess costs to private and governmental health insurers annually. Although difficult to accurately assess, prescription opioid abuse also leads to increased insurance costs in the form of property and liability claims, and costs to state and local governments for judicial, emergency, and social services. This manuscript's objective is to provide payers with strategies to control these costs, while supporting safe use of prescription opioid medications for patients with chronic pain.
  
  
  METHODS
  A Tufts Health Care Institute Program on Opioid Risk Management meeting was convened in June 2010 with private and public payer representatives, public health and law enforcement officials, pain specialists, and other stakeholders to present research and develop recommendations on solutions that payers might implement to combat this problem.
  
  
  RESULTS
  While protecting access to prescription opioids for patients with pain, private and public payers can implement strategies to mitigate financial risks associated with opioid abuse, using internal strategies such as formulary controls, claims data surveillance, and claims matching; and external policies and procedures that support and educate physicians on reducing opioid risks among patients with chronic pain.
  
  
  CONCLUSIONS
  Reimbursement policies, incentives, and health technology systems that encourage physicians to use universal precautions, to consult prescription monitoring program (PMP) data, and to implement Screening, Brief Intervention, and Referral to Treatment protocols have a high potential to reduce insurer risks while addressing a serious public health problem.
authors.affiliation: Tufts University School of Medicine, Tufts Health Care Institute Program on Opioid Risk Management, Boston, MA, USA. nkatz@analgesicsolutions.com
authors.forename: Nathaniel P
authors.initials: NP
authors.lastname: Katz
authors.forename: Howard
authors.initials: H
authors.lastname: Birnbaum
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Brennan
authors.forename: John D
authors.initials: JD
authors.lastname: Freedman
authors.forename: Gary P
authors.initials: GP
authors.lastname: Gilmore
authors.forename: Dennis
authors.initials: D
authors.lastname: Jay
authors.forename: George A
authors.initials: GA
authors.lastname: Kenna
authors.forename: Bertha K
authors.initials: BK
authors.lastname: Madras
authors.forename: Lisa
authors.initials: L
authors.lastname: McElhaney
authors.forename: Roger D
authors.initials: RD
authors.lastname: Weiss
authors.forename: Alan G
authors.initials: AG
authors.lastname: White
mesh_terms: D000701:Analgesics, Opioid; D003363:Cost Control / Q000379:methods; D006801:Humans; D008329:Managed Care Programs / Q000191:economics*; D055553:Prescription Drugs; D012308:Risk Management / Q000379:methods; D015813:Substance Abuse Detection; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000191:economics
chemical_list: D000701:Analgesics, Opioid; D055553:Prescription Drugs